Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Mol Vis ; 15: 1325-31, 2009 Jul 08.
Artigo em Inglês | MEDLINE | ID: mdl-19597567

RESUMO

PURPOSE: To screen cytochrome P4501B1 (CYP1B1) for causative mutations in Omani patients with a clinical diagnosis of primary congenital glaucoma (PCG) METHODS: Nine PCG families were recruited for the study. All patients underwent detailed clinical examinations to confirm the diagnosis of PCG. The families of index patients were also examined. Genealogical information was obtained by pedigree analysis. The primary candidate gene, CYP1B1, was amplified from genomic DNA, sequenced, and analyzed in patients to identify the disease-causing mutations. RESULTS: Eight of the nine PCG families were consanguineous (89%). Molecular analysis of CYP1B1 showed three distinct mutations, p.G61E, p.D374N, and p.R368H, in seven of nine unrelated PCG index patients (78%). Six patients had homozygous mutations and one had a compound heterozygous mutation. Causative mutations were not identified in two families. In family 4, the index patient was found to be heterozygous for the p.E229K variant. In family 6, although affected individuals were found to be homozygous in the CYP1B1 region, no mutation could be identified. CONCLUSIONS: This study indicates that CYP1B1 could be the predominant cause of PCG in the Omani population (78%). Omani PCG patients show allelic heterogeneity. Further studies are needed to delineate the spectrum of CYP1B1mutations in Omani PCG families and to identify new or modifier genes contributing to the manifestations of PCG in this region.


Assuntos
Hidrocarboneto de Aril Hidroxilases/genética , Povo Asiático/genética , Glaucoma/congênito , Glaucoma/enzimologia , Mutação/genética , Adolescente , Adulto , Sequência de Bases , Criança , Pré-Escolar , Citocromo P-450 CYP1B1 , Feminino , Glaucoma/genética , Haplótipos , Humanos , Lactente , Recém-Nascido , Masculino , Dados de Sequência Molecular , Omã , Linhagem , Projetos Piloto
2.
J Med Chem ; 51(13): 3961-70, 2008 Jul 10.
Artigo em Inglês | MEDLINE | ID: mdl-18533711

RESUMO

Glycosylated diazeniumdiolates of structure R 2NN(O)NO-R' (R' = a saccharide residue) are potential prodrugs of the nitric oxide (NO)-releasing but acid-sensitive R 2NN(O)NO (-) ion. Moreover, cleaving the acid-stable glycosides under alkaline conditions provides a convenient protecting group strategy for diazeniumdiolate ions. Here, we report comparative hydrolysis rate data for five representative glycosylated diazeniumdiolates at pH 14, 7.4, and 3.8-4.6 as background for further developing both the protecting group application and the ability to target NO pharmacologically to macrophages harboring intracellular pathogens. Confirming the potential in the latter application, adding R 2NN(O)NO-GlcNAc (where R 2N = diethylamino or pyrrolidin-l-yl and GlcNAc = N-acetylglucosamin-l-yl) to cultures of infected mouse macrophages that were deficient in inducible NO synthase caused rapid death of the intracellular protozoan parasite Leishmania major with no host cell toxicity.


Assuntos
Compostos Azo/síntese química , Compostos Azo/farmacologia , Macrófagos/efeitos dos fármacos , Macrófagos/metabolismo , Óxido Nítrico/biossíntese , Oxigênio/química , Pró-Fármacos/farmacologia , Animais , Antiprotozoários/síntese química , Antiprotozoários/química , Antiprotozoários/farmacologia , Compostos Azo/química , Carboidratos/química , Cristalografia por Raios X , Glicosilação , Humanos , Concentração de Íons de Hidrogênio , Hidrólise , Leishmania major , Camundongos , Modelos Moleculares , Estrutura Molecular , Pró-Fármacos/síntese química , Pró-Fármacos/química
3.
J Immunol ; 171(9): 4561-8, 2003 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-14568929

RESUMO

Inducible NO synthase (iNOS) and its generation of NO from L-arginine are subject to transcriptional as well as posttranscriptional control by cytokines. In this study, we describe a novel, translational mechanism of iNOS regulation by arginine availability. Using mouse inflammatory peritoneal macrophages stimulated with IFN-gamma plus LPS, we demonstrate that the suppression of iNOS protein, which is observed after a 16-h (but not after a 6-h) pretreatment with IL-13, despite an unaltered iNOS mRNA level, results from arginine depletion by arginase. The addition of arginase inhibitors (in the pretreatment phase) or of arginine (in the stimulation phase) completely blocked the down-regulation of iNOS protein by IL-13. The rescuing effect of arginine supplementation was not due to a positive feedback regulation of iNOS expression via enhanced production of NO. A striking suppression of iNOS protein (but not of iNOS mRNA) was also seen, when IL-13 was replaced by purified arginase or when macrophages were stimulated with IFN-gamma/LPS in arginine-free medium. Arginine deficiency specifically impaired the de novo synthesis and the stability of iNOS protein, but did not affect the production of TNF and the overall protein synthesis of the macrophages. From these results, we conclude that arginine not only functions as a substrate for iNOS, but is also critical for maintaining normal levels of iNOS protein in cytokine-stimulated macrophages.


Assuntos
Arginina/análogos & derivados , Arginina/metabolismo , Líquido Ascítico/enzimologia , Líquido Ascítico/imunologia , Interleucina-13/fisiologia , Macrófagos Peritoneais/enzimologia , Macrófagos Peritoneais/imunologia , Óxido Nítrico Sintase/genética , Biossíntese de Proteínas/imunologia , Animais , Arginase/antagonistas & inibidores , Arginase/biossíntese , Arginina/deficiência , Arginina/farmacologia , Arginina/fisiologia , Líquido Ascítico/patologia , Contagem de Células , Células Cultivadas , Meios de Cultivo Condicionados , Relação Dose-Resposta Imunológica , Inibidores Enzimáticos/farmacologia , Estabilidade Enzimática , Feminino , Macrófagos Peritoneais/metabolismo , Camundongos , Óxido Nítrico/biossíntese , Óxido Nítrico/fisiologia , Óxido Nítrico Sintase/antagonistas & inibidores , Óxido Nítrico Sintase/biossíntese , Óxido Nítrico Sintase Tipo II
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...